Altimmune Inc (ALT)
2.96
-0.07 -2.31%
NASDAQ
Mar 21, 11:47
Delayed 2m
USD
View All Key Stats
ALT Key Stats
| Income Statement | |
| Revenue (TTM) | 10.55M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -36.97 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -23.49M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -89.25% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | Upgrade |
| Price and Valuation | |
| Market Cap | 26.87M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | 0.2449 |
| PE Ratio (TTM) | -- |
| Price to Book Value | 0.6772 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | Upgrade |
| Free Cash Flow (Quarterly) | -1.191M |
| Return on Equity (TTM) | Upgrade |
View All ALT News
ALT News
-
WireHeadlineTime (ET)
-
SA Breaking News03/20 09:12
-
SA Breaking News03/19 12:43
-
Yahoo03/19 12:21
-
SA Breaking News03/19 11:02
-
PR Newswire03/19 09:31
-
MT Newswires03/19 09:13
-
SA Breaking News03/19 09:13
-
Yahoo03/19 08:12
-
SA Breaking News03/19 08:00
-
MT Newswires03/19 07:56
View All Events
ALT Events
| Date | Type | Description |
|---|---|---|
| 09/14/2018 | Splits | Ratio: 333333:10000000 |
| 08/10/2018 | Misc | Altimmune Inc Second Quarter Earnings Conference Call in 2018 |
ALT Fundamentals
Income Statement View Statement
ALT Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
ALT One Page Reports
- One Page Report Download
ALT Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 2.96 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Edit
Profile
- URL: http://www.altimmune.com
- Investor Relations URL: http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome
- HQ State/Province: Maryland
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: N/A
- Last Earnings Release: Mar. 14, 2018
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: Jan. 20, 2017
- Description: Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. The firm's product candidates include Nasovax, Heptcell, Sparvax-L, Nasoshield, and Oncosyn. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.
ALT Excel Add-In Codes
- Name: =YCI("ALT","name")
- Description: =YCI("ALT","description")
- Sector: =YCI("ALT","sector")
- Industry: =YCI("ALT","industry")
- Est. Current Fiscal Year End: =YCI("ALT","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other ALT Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ALT Tweets Stocktwits
Advertisement
